Male breast cancer: an update in diagnosis, treatment and molecular profiling.
Significant advances have been made in the diagnosis and treatment of female breast cancer, resulting in a decline in incidence and a global improvement in clinical outcome. The statistics for male breast cancer (MBC) stand in sharp contrast-over the past several decades, there has been a steady rise in the incidence of this disease, and clinical outcome has improved at a much slower pace. In the current review, the clinicopathologic features of MBC are described in detail. An emphasis is placed on molecular profiling of MBC, which may identify candidate biomarkers and putative targets for pharmacologic intervention. The current role of cytotoxic chemotherapy and endocrine therapy (including tamoxifen, aromatase inhibitors and GnRH analogues) is defined in the context of currently available studies. Furthermore, the potential role of targeted agents, including HER2-directed therapies, PARP inhibitors, and angiogenesis inhibitors, is delineated.
Division of Genitourinary Malignancies, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Susan
S
Onami
Melanie
M
Ozaki
Joanne E
JE
Mortimer
Sumanta Kumar
SK
Pal
D019313:BRCA1 Protein / Q000172:deficiency; D024682:BRCA2 Protein / Q000172:deficiency; D018567:Breast Neoplasms, Male / Q000175:diagnosis / Q000378:metabolism / Q000628:therapy*; D002277:Carcinoma / Q000175:diagnosis / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D008297:Male; D012307:Risk Factors
D019313:BRCA1 Protein; D024682:BRCA2 Protein